Author:
Gan Hui K.,Lee J. Jack,Siu Lillian L.
Reference60 articles.
1. U.S. Food and Drug Administration, Title 21 – Food and Drugs; Chapter 1 – Food and Drug Administration; Subchapter D – Drugs for Human Use, Department of Health and Human Services. 2007, U.S. Food and Drug Administration, Silver Spring, MD.
2. Baar, J. and I. Tannock, Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials. Journal of Clinical Oncology, 1989. 7(7): pp. 969–978.
3. Perrone, F., et al., Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncology, 2003. 4(5): pp. 305–311.
4. Lee, J.J. and L. Feng, Randomized phase II designs in cancer clinical trials: current status and future directions. Journal of Clinical Oncology, 2005. 23(19): pp. 4450–4457.
5. Zia, M.I., et al., Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. Journal of Clinical Oncology, 2005. 23(28): pp. 6982–6991.